Literature DB >> 29651128

Encorafenib - a new agent for advanced-stage disease.

Peter Sidaway1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29651128     DOI： 10.1038/s41571-018-0019-x

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.

Authors:  Alberto Meneguzzo; Annalisa Lazzarotto; Mauro Alaibac
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

2.  Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy.

Authors:  Yanan Li; Qingrong Dong; Yukun Cui
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.